Bristol Myers Squibb is already aiming to launch more than 10 new medicines by 2030. | SAN FRANCISCO—Bristol Myers Squibb is ...

BMS looks forward to pivotal readouts for six assets in 2026, ensuring profits after patent expiries for Opdivo and Eliquis.

Mature biopharma deals are stealing all the headlines, but Bristol Myers Squibb’s Robert Plenge says the company’s deals with ...

This effort, undertaken by Bristol Myers Squibb and agency partner Real Chemistry, is part of the Champions in Care campaign.

[Editor’s note: The hacker requested that we remove the image for legal reasons, so it’s blurry now. We hope all’s well!] Lithium technology has ushered in a new era of batteries with exceptionally ...

Bristol Myers Squibb (BMS) has agreed as part of a deal with the US government to provide Eliquis (apixaban) free of charge ...

After several years of turning out solid growth, Bristol Myers Squibb knows it’s nearing a patent cliff that’ll wreak havoc later this decade. Still, the company believes a “diversified” ...